Ray Dalio’s ELV Holdings & Trades

First Buy
Q4 2014
Duration Held
38 Quarters
Largest Add
Q4 2024
+91,849 Shares
Current Position
55,203 Shares
$17.84 M Value

Ray Dalio's ELV Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 55,203 shares of Elevance Health, Inc. (ELV) worth $17.84 M, representing 0.07% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 38 quarters.

Based on 13F filings, Ray Dalio has maintained a strategic position in ELV, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 91,849 shares. Largest reduction occurred in Q4 2019, reducing 129,345 shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Elevance Health (ELV) Holding Value Over Time

Track share changes against reported price movement

Quarterly Elevance Health (ELV) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2014 +27,141 New Buy 27,141 $125.68
Q1 2015 -7,600 Reduce 28.00% 19,541 $154.39
Q2 2015 +14,000 Add 71.64% 33,541 $164.13
Q3 2015 +2,600 Add 7.75% 36,141 $140.01
Q4 2015 -36,141 Sold Out 0 $0.00
Q1 2016 +18,900 New Buy 18,900 $138.99
Q2 2016 +24,100 Add 127.51% 43,000 $131.35
Q3 2016 +31,679 Add 73.67% 74,679 $125.31
Q4 2016 -75 Reduce 0.10% 74,604 $143.77
Q1 2017 -74,604 Sold Out 0 $0.00
Q3 2017 +6,199 New Buy 6,199 $189.87
Q4 2017 -6,199 Sold Out 0 $0.00
Q1 2018 +7,493 New Buy 7,493 $219.67
Q2 2018 -7,493 Sold Out 0 $0.00
Q1 2019 +21,217 New Buy 21,217 $286.99
Q2 2019 +23,117 Add 108.96% 44,334 $282.20
Q3 2019 +85,011 Add 191.75% 129,345 $240.10
Q4 2019 -129,345 Sold Out 0 $0.00
Q1 2020 +7,167 New Buy 7,167 $227.01
Q2 2020 -2,268 Reduce 31.65% 4,899 $262.91
Q3 2020 -4,899 Sold Out 0 $0.00
Q3 2021 +2,183 New Buy 2,183 $372.88
Q4 2021 +16,779 Add 768.62% 18,962 $463.56
Q1 2022 +16,505 Add 87.04% 35,467 $491.22
Q2 2022 +42,365 Add 119.45% 77,832 $482.58
Q3 2022 -30,110 Reduce 38.69% 47,722 $454.23
Q4 2022 +37,582 Add 78.75% 85,304 $512.97
Q1 2023 -50,917 Reduce 59.69% 34,387 $459.81
Q2 2023 +32,908 Add 95.70% 67,295 $444.29
Q3 2023 +28,008 Add 41.62% 95,303 $435.42
Q4 2023 +32,942 Add 34.57% 128,245 $471.56
Q1 2024 -64,905 Reduce 50.61% 63,340 $518.54
Q2 2024 -21,754 Reduce 34.34% 41,586 $541.86
Q3 2024 +20,463 Add 49.21% 62,049 $520.00
Q4 2024 +91,849 Add 148.03% 153,898 $368.90
Q1 2025 -70,557 Reduce 45.85% 83,341 $434.96
Q2 2025 -24,504 Reduce 29.40% 58,837 $388.96
Q3 2025 -3,634 Reduce 6.18% 55,203 $323.12

Ray Dalio's Elevance Health Investment FAQs

Ray Dalio first purchased Elevance Health, Inc. (ELV) in Q4 2014, acquiring 27,141 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Elevance Health, Inc. (ELV) for 38 quarters since Q4 2014.

Ray Dalio's largest addition to Elevance Health, Inc. (ELV) was in Q4 2024, adding 153,898 shares worth $56.77 M.

According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 55,203 shares of Elevance Health, Inc. (ELV), valued at approximately $17.84 M.

As of the Q3 2025 filing, Elevance Health, Inc. (ELV) represents approximately 0.07% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Elevance Health, Inc. (ELV) was 153,898 shares, as reported at the end of Q4 2024.